Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 12% to HKD 1.87, with a trading volume of HKD 18.44 million [1] Group 1: Financial Actions - Beihai Kangcheng announced the issuance of 74.97 million new shares to Baiyang Pharmaceutical (301015.SZ) at a price of HKD 1.34 per share, representing a discount of 19.76% compared to the last trading price before suspension [1] - The net proceeds from the subscription amount to approximately HKD 98.66 million, which will be used for the development of commercialized products, marketing and promotional activities, loan repayment, and daily operations [1] Group 2: Strategic Partnerships - The company has entered into a strategic cooperation and exclusive commercial service agreement with subsidiaries of Baiyang Pharmaceutical, designating Baiyang's subsidiary as the exclusive sales organization for promoting several of the group's products in mainland China, Hong Kong, and Macau [1] - Following the share issuance, Baiyang Pharmaceutical will hold 14.99% of Beihai Kangcheng's equity, and it has stated that it does not intend to acquire any controlling stake in the company within the next three years [1]